<?xml version="1.0" encoding="UTF-8"?>
<ref id="B180-molecules-26-00431">
 <label>180.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Kannan</surname>
    <given-names>P.</given-names>
   </name>
   <name>
    <surname>Telu</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Shukla</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Ambudkar</surname>
    <given-names>S.V.</given-names>
   </name>
   <name>
    <surname>Pike</surname>
    <given-names>V.W.</given-names>
   </name>
   <name>
    <surname>Halldin</surname>
    <given-names>C.</given-names>
   </name>
   <name>
    <surname>Gottesman</surname>
    <given-names>M.M.</given-names>
   </name>
   <name>
    <surname>Innis</surname>
    <given-names>R.B.</given-names>
   </name>
   <name>
    <surname>Hall</surname>
    <given-names>M.D.</given-names>
   </name>
  </person-group>
  <article-title>The “Specific” P-Glycoprotein Inhibitor Tariquidar Is Also a Substrate and an Inhibitor for Breast Cancer Resistance Protein (BCRP/ABCG2)</article-title>
  <source>ACS Chem. Neurosci.</source>
  <year>2011</year>
  <volume>2</volume>
  <fpage>82</fpage>
  <lpage>89</lpage>
  <pub-id pub-id-type="doi">10.1021/cn100078a</pub-id>
  <pub-id pub-id-type="pmid">22778859</pub-id>
 </element-citation>
</ref>
